Search

Displaying results 1821 - 1830 of 4692 in total
  1. Drug

    Fremanezumab

    go.drugbank.com/drugs/DB14041
    ApprovedInvestigational

    [L11749] It was developed by Teva Pharmaceuticals USA and approved by the FDA in September 2018.

  2. Drug

    Crinecerfont

    go.drugbank.com/drugs/DB18518
    ApprovedInvestigational

    [A264818] Standard therapy involves cortisol replacement, but typically requires supraphysiological glucocorticoid doses to lower both ACTH and adrenal androgens, resulting in chronic glucocorticoid overexposure … Patients with congenital adrenal hyperplasia (CAH) face two major problems: adrenal insufficiency, caused by insufficient endogenous cortisol production, and androgen excess, caused by a counter-regulatory

  3. Drug

    Mupirocin

    go.drugbank.com/drugs/DB00410
    ApprovedInvestigationalVet approved

    [L10580] It primarily works by inhibiting bacterial protein synthesis. … _ and traumatic skin lesions due to secondary skin infections caused by _S. aureus_ and _S. pyogenes_.

  4. Drug

    Docetaxel

    go.drugbank.com/drugs/DB01248
    ApprovedInvestigational

    Docetaxel binds to microtubules but does not interact with dimeric tubulin. … [L46466] Docetaxel was approved by the FDA in 1996 and is available in solution for injection for intravenous or parenteral administration.[A259676]

  5. Drug

    Marnetegragene autotemcel

    go.drugbank.com/drugs/DB17595
    Approved

    [L56116, A275467] Allogeneic hematopoietic stem cell transplant is a curative option but is limited by issues such as donor availability, a high incidence of graft-versus-host disease, and graft failure

  6. Drug

    GTB-3550

    go.drugbank.com/drugs/DB18494
    Investigational

    GTB-3550 is a single-chain, tri-specific scFv recombinant fusion protein conjugate composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form

  7. Drug

    Bebtelovimab

    go.drugbank.com/drugs/DB16755
    ApprovedWithdrawn

    On November 30, 2022, the EUA for bebtelovimab was officially withdrawn due to a lack of efficacy against Omicron subvariants, therefore bebtelovimab is no longer authorized for emergency use in the US … [L40328] Bebtelovimab was issued an emergency use authorization (EUA) by the FDA on February 11, 2022, for the treatment of mild-to-moderate COVID-19 in select patients.

  8. Drug

    Roxadustat

    go.drugbank.com/drugs/DB04847
    ApprovedInvestigational

    [A245393] Roxadustat was first approved by the European Commission in August 2021.[L40323] … It works by reducing the breakdown of the hypoxia-inducible factor (HIF), which is a transcription factor that stimulates red blood cell production in response to low oxygen levels.

  9. Drug

    D2C7 immunotoxin

    go.drugbank.com/drugs/DB17540
    Investigational

    D2C7 immunotoxin (D2C7-IT) is an investigational dual-specific monoclonal antibody targeting EGFRwt and EGFRvIII with a genetically engineered form of the _Pseudomonas exotoxin_, PE38-KDEL.

  10. Drug

    Fluticasone

    go.drugbank.com/drugs/DB13867
    ApprovedInvestigationalWithdrawn

    Fluticasone is a synthetic glucocorticoid available as 2 esters, DB08906 and DB00588 [FDA Label]. These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications [FDA Label]. DB00588 was ...